President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

Europe 'Must Fix' Weaknesses to Compete, EU's Von der Leyen Says EU nations must work together quickly to help the bloc compete against global economic powerhouses like China and the U.S., European ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

Medicare’s $35 insulin price cap was signed into law through the Inflation Reduction Act, which means it would take another law passed by Congress to change or get rid of the price cap. In 2023, ...